Effect of sitagliptin on intrahepatic lipid content and body fat in patients with type 2 diabetes

Diabetes Research and Clinical Practice

Volumn 109, Issue 1, 2015, Pages 199-205

  Kato, Hiroyuki ^a   Nagai, Yoshio ^a   Ohta, Akio ^a   Tenjin, Ayumi ^a   Nakamura, Yuta ^a   Tsukiyama, Hidekazu ^a   Sasaki, Yosuke ^a   Fukuda, Hisashi ^a   Ohshige, Toshihiko ^a   Terashima, Yuko ^a   Sada, Yukiyoshi ^a   Kondo, Akihiko ^a   Sasaoka, Toshiyasu ^b   Tanaka, Yasushi ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Body fat; DPP 4 inhibitor; Fatty liver; Sitagliptin; Type 2 diabetes

Indexed keywords

ADIPONECTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; FATTY ACID; GLIMEPIRIDE; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; ORAL ANTIDIABETIC AGENT; SITAGLIPTIN; SULFONYLUREA; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; BODY FAT; BODY MASS; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DOSE TITRATION; DUAL ENERGY X RAY ABSORPTIOMETRY; FAT MASS; FATTY LIVER; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; JAPANESE (PEOPLE); LIPID COMPOSITION; LOW DRUG DOSE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PROSPECTIVE STUDY; PROTON NUCLEAR MAGNETIC RESONANCE; ADIPOSE TISSUE; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; ECHOGRAPHY; GLUCOSE BLOOD LEVEL; JAPAN; LIPID METABOLISM; LIVER; METABOLISM; MIDDLE AGED; OVERWEIGHT; PHOTON ABSORPTIOMETRY; RANDOMIZED CONTROLLED TRIAL;

ABSORPTIOMETRY, PHOTON; ADIPOSE TISSUE; ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FATTY LIVER; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; JAPAN; LIPID METABOLISM; LIVER; MALE; MIDDLE AGED; OVERWEIGHT; SITAGLIPTIN PHOSPHATE; SULFONYLUREA COMPOUNDS;

EID: 84930824303     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2015.04.008     Document Type: Article

References (30)

1. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012, 55(6):1577-1596.
2. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35(6):1364-1379.
3. Kim Y.G., Hahn S., Oh T.J., Kwak S.H., Park K.S., Cho Y.M. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia 2013, 56(4):696-708.
4. Amori R.E., Lau J., Pittas A.G. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007, 298(2):194-206.
5. Neumiller J.J., Wood L., Campbell R.K. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Pharmacotherapy 2010, 30(5):463-484.
6. Gupta N.A., Mells J., Dunham R.M., Grakoui A., Handy J., Saxena N.K., et al. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 2010, 51(5):1584-1592.
7. Svegliati-Baroni G., Saccomanno S., Rychlicki C., Agostinelli L., De Minicis S., Candelaresi C., et al. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signaling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int 2011, 31(9):1285-1297.
8. Cuthbertson D.J., Irwin A., Gardner C.J., Daousi C., Purewal T., Furlong N., et al. Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists. PLoS ONE 2012, 7(12):e50117.
9. Aoki K., Kamiyama H., Yoshimura K., Shibuya M., Masuda K., Terauchi Y. Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin. Acta Diabetol 2012, 49(3):225-230.
10. Agersø H., Jensen L.B., Elbrønd B., Rolan P., Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002, 45(2):195-202.
11. Kern M., Klöting N., Niessen H.G., et al. Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity. PLoS ONE 2012, 7:e38744.
12. Jung Y.A., Choi Y.K., Jung G.S., Seo H.Y., Kim H.S., Jang B.K., et al. Sitagliptin attenuates methionine/choline-deficient diet-induced steatohepatitis. Diabetes Res Clin Pract 2014, 105(1):47-57.
13. Osawa H., Mori Y. Sonographic diagnosis of fatty liver using a histogram technique that compares liver and renal cortical echo amplitudes. J Clin Ultrasound 1996, 24:25-29.
14. Iwamoto Y., Taniguchi T., Nonaka K., Okamoto T., Okuyama K., Arjona Ferreira J.C., et al. Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Endocr J 2010, 57(5):383-394.
15. Rosskamp R., Wernicke-Panten K., Draeger E. Clinical profile of the novel sulphonylurea glimepiride. Diabetes Res Clin Pract 1996, 31(Suppl):S33-S42.
16. Tamura Y., Tanaka Y., Sato F., Choi J.B., Watada H., Niwa M., et al. Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2005, 90(6):3191-3196.
17. Sato F., Tamura Y., Watada H., Kumashiro N., Igarashi Y., Uchino H., et al. Effects of diet-induced moderate weight reduction on intrahepatic and intramyocellular triglycerides and glucose metabolism in obese subjects. J Clin Endocrinol Metab 2007, 92(8):3326-3329.
18. Kirk E., Reeds D.N., Finck B.N., Mayurranjan S.M., Patterson B.W., Klein S. Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. Gastroenterology 2009, 136(5):1552-1560.
19. Sada Y., Katabami T., Asai S., Sato T., Furukawa K., Ishii S., et al. Intrahepatic lipid content is linked to insulin resistance in obese subjects. Obes Res Clin Pract 2011, 5(2):e79-e156.
20. Tamura Y., Watada H., Sato F., Kumashiro N., Sakurai Y., Hirose T., et al. Effects of metformin on peripheral insulin sensitivity and intracellular lipid contents in muscle and liver of overweight Japanese subjects. Diabetes Obes Metab 2008, 10(9):733-738.
21. Stephenne X., Foretz M., Taleux N., van der Zon G.C., Sokal E., Hue L., et al. Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status. Diabetologia 2011, 54(12):3101-3110.
22. Viollet B., Guigas B., Sanz Garcia N., Leclerc J., Foretz M., Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) 2012, 122(6):253-270.
23. Viollet B., Guigas B., Leclerc J., Hébrard S., Lantier L., Mounier R., et al. AMP-activated protein kinase in the regulation of hepatic energy metabolism: from physiology to therapeutic perspectives. Acta Physiol (Oxf) 2009, 196(1):81-98.
24. Ben-Shlomo S., Zvibel I., Shnell M., Shlomai A., Chepurko E., Halpern Z., et al. Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. J Hepatol 2011, 54(6):1214-1223.
25. Svegliati-Baroni G., Saccomanno S., Rychlicki C., Agostinelli L., De Minicis S., Candelaresi C., et al. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int 2011, 31(9):1285-1297.
26. Getty-Kaushik L., Song D.H., Boylan M.O., Corkey B.E., Wolfe M.M. Glucose-dependent insulinotropic polypeptide modulates adipocyte lipolysis and reesterification. Obesity (Silver Spring) 2006, 14(7):1124-1131.
27. Sancho V., Trigo M.V., Martín-Duce A., Gonz Lez N., Acitores A., Arnés L., et al. Effect of GLP-1 on d-glucose transport, lipolysis and lipogenesis in adipocytes of obese subjects. Int J Mol Med 2006, 17(6):1133-1137.
28. Vendrell J., El Bekay R., Peral B., García-Fuentes E., Megia A., Macias-Gonzalez M., et al. Study of the potential association of adipose tissue GLP-1 receptor with obesity and insulin resistance. Endocrinology 2011, 152(11):4072-4079.
29. Ceperuelo-Mallafré V., Duran X., Pachón G., Roche K., Garrido-Sánchez L., Vilarrasa N., et al. Disruption of GIP/GIPR axis in human adipose tissue is linked to obesity and insulin resistance. J Clin Endocrinol Metab 2014, 99(5):E908-E919.
30. Aso Y., Ozeki N., Terasawa T., Naruse R., Hara K., Suetsugu M., et al. Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea. Transl Res 2012, 159(1):25-31.